Cargando…
Updated anaphylaxis guidelines: management in infants and children
Severe allergic reactions (anaphylaxis) are unpredictable, and initial signs of what could be fatal anaphylaxis can be mild Adrenaline (epinephrine) remains the first-line drug of choice for the acute management of anaphylaxis and should be administered early There are no contraindications to intram...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
NPS MedicineWise
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236874/ https://www.ncbi.nlm.nih.gov/pubmed/34211247 http://dx.doi.org/10.18773/austprescr.2021.016 |
_version_ | 1783714635755552768 |
---|---|
author | Frith, Katie Smith, Jill Joshi, Preeti Ford, Lara S Vale, Sandra |
author_facet | Frith, Katie Smith, Jill Joshi, Preeti Ford, Lara S Vale, Sandra |
author_sort | Frith, Katie |
collection | PubMed |
description | Severe allergic reactions (anaphylaxis) are unpredictable, and initial signs of what could be fatal anaphylaxis can be mild Adrenaline (epinephrine) remains the first-line drug of choice for the acute management of anaphylaxis and should be administered early There are no contraindications to intramuscular adrenaline in the treatment of anaphylaxis Correct positioning of the patient is vital as death can occur within minutes if a patient stands, walks or sits up suddenly. Position the patient correctly first and then promptly administer intramuscular adrenaline Updated guidelines by the Australasian Society of Clinical Immunology and Allergy now recommend that the 0.15 mg adrenaline injector device may be prescribed for infants and children weighing 7.5–10 kg. The recommendation to use the 0.3 mg adrenaline injector device for those over 20 kg remains unchanged The adrenaline doses in Australian Prescriber’s anaphylaxis wallchart remain valid |
format | Online Article Text |
id | pubmed-8236874 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | NPS MedicineWise |
record_format | MEDLINE/PubMed |
spelling | pubmed-82368742021-06-30 Updated anaphylaxis guidelines: management in infants and children Frith, Katie Smith, Jill Joshi, Preeti Ford, Lara S Vale, Sandra Aust Prescr Article Severe allergic reactions (anaphylaxis) are unpredictable, and initial signs of what could be fatal anaphylaxis can be mild Adrenaline (epinephrine) remains the first-line drug of choice for the acute management of anaphylaxis and should be administered early There are no contraindications to intramuscular adrenaline in the treatment of anaphylaxis Correct positioning of the patient is vital as death can occur within minutes if a patient stands, walks or sits up suddenly. Position the patient correctly first and then promptly administer intramuscular adrenaline Updated guidelines by the Australasian Society of Clinical Immunology and Allergy now recommend that the 0.15 mg adrenaline injector device may be prescribed for infants and children weighing 7.5–10 kg. The recommendation to use the 0.3 mg adrenaline injector device for those over 20 kg remains unchanged The adrenaline doses in Australian Prescriber’s anaphylaxis wallchart remain valid NPS MedicineWise 2021-06-01 2021-06 /pmc/articles/PMC8236874/ /pubmed/34211247 http://dx.doi.org/10.18773/austprescr.2021.016 Text en (c) NPS MedicineWise https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND) 4.0 License. |
spellingShingle | Article Frith, Katie Smith, Jill Joshi, Preeti Ford, Lara S Vale, Sandra Updated anaphylaxis guidelines: management in infants and children |
title | Updated anaphylaxis guidelines: management in infants and children |
title_full | Updated anaphylaxis guidelines: management in infants and children |
title_fullStr | Updated anaphylaxis guidelines: management in infants and children |
title_full_unstemmed | Updated anaphylaxis guidelines: management in infants and children |
title_short | Updated anaphylaxis guidelines: management in infants and children |
title_sort | updated anaphylaxis guidelines: management in infants and children |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236874/ https://www.ncbi.nlm.nih.gov/pubmed/34211247 http://dx.doi.org/10.18773/austprescr.2021.016 |
work_keys_str_mv | AT frithkatie updatedanaphylaxisguidelinesmanagementininfantsandchildren AT smithjill updatedanaphylaxisguidelinesmanagementininfantsandchildren AT joshipreeti updatedanaphylaxisguidelinesmanagementininfantsandchildren AT fordlaras updatedanaphylaxisguidelinesmanagementininfantsandchildren AT valesandra updatedanaphylaxisguidelinesmanagementininfantsandchildren |